ArticleAdvanced healthcare materials2025
Mechanobiologically Engineered Mimicry of Extracellular Vesicles for Improved Systemic Biodistribution and Anti-Inflammatory Treatment Efficacy in Rheumatoid Arthritis.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recent Advances in Microenvironment-Responsive Materials for Periodontitis Therapy.International journal of molecular sciences · 2026Review
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
- Targeted delivery of Prussian blue modified exosomes to CD90-expressing synovial fibroblasts for Rheumatoid arthritis immunotherapy.Materials today. Bio · 2025Article
- Mechanobiologically Engineered Mimicry of Extracellular Vesicles for Improved Systemic Biodistribution and Anti-Inflammatory Treatment Efficacy in Rheumatoid Arthritis.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Liposomal membrane elasticity is a controlling parameter in designing liposome-based drug delivery systems and significantly affects biodistribution and biofunctional effects. Although extensively investigated in tumor models, the impact of liposomal membrane elasticity on rheumatoid arthritis (RA) remains underexplored. RA presents unique challenges, such as tortuous blood vessels, increased permeability, and chronic inflammation, which necessitate a specialized drug delivery strategy. This study aims to address these challenges by developing an engineered mimicry of extracellular vesicles (EVs) that is based on a lipid/polymer hybrid system incorporating poly(ethylene oxide)-b-poly(ε-caprolactone)-b-poly(ethylene oxide) (PEO-b-PCL-b-PEO) to improve mechanical robustness and therapeutic performance.Tri-ARTEX is developed as a lipid/polymer hybrid liposome encapsulating stem cell extract (CE) and microRNA (AntagomiR155), and tuned its membrane elasticity by varying the PEO-b-PCL-b-PEO fraction. Tri-ARTEX exhibited enhanced cellular uptake in Raw 264.7 macrophages as the PEO-b-PCL-b-PEO fraction increases. However, semi-elastic Tri-ARTEX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.